Jonathan B. Angel

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink et al. · The Lancet · 2017 · 492 citations

Treatment And Prevention, Medicine, Phase 2B +8

Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Shawn D. Aaron, Jonathan B. Angel, Mary Lunau et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 466 citations

Asthma, Inflammatory Lung Disease, Advanced Lung Disease +17

A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses.

Amy Chernoff, Eric V. Granowitz, Leland Shapiro et al. · The Journal of Immunology · 1995 · 420 citations

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures

Mansoureh Hakimi, Thirumahal Selvanantham, Erika Swinton et al. · Journal of Neural Transmission · 2011 · 287 citations

Inflammation, Tissue Immune Cells, Disease-linked Lrrk2 +15